Holen Sie sich die Stockscreener-App
20.34
0.99%
0.20
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
What is HC Wainwright's Forecast for VRDN FY2024 Earnings? - MarketBeat
Viridian Therapeutics’ (VRDN) Buy Rating Reiterated at Needham & Company LLC - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $34.00 - Defense World
FY2024 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for VRDN FY2024 Earnings? - Defense World
(VRDN) Trading Signals - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Should You Sell? - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Viridian Ther - GuruFocus.com
Paradigm Biocapital Advisors LP Increases Stake in Viridian Ther - GuruFocus.com
Wedbush Has Pessimistic Outlook of VRDN FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat
What is Lifesci Capital's Estimate for VRDN FY2024 Earnings? - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Viridian Therapeutics Inc (VRDN) Quarterly 10-Q Report - Quartzy
Q1 Earnings Estimate for VRDN Issued By Wedbush - MarketBeat
HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics stock target upgraded, keeps buy on veligrotug outlook By Investing.com - Investing.com Canada
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate - Simply Wall St
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses - TipRanks
Viridian Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.09, revenue fell short of estimates - Investing.com UK
Viridian Reports Phase 3 Success, Expands Pipeline With $753M War Chest | VRDN Stock News - StockTitan
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighTime to Buy? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Grants 150K Stock Options to New Employees in Retention Push | VRDN Stock News - StockTitan
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Net Present Value Model: Viridian Therapeutics Inc’s Veligrotug - GlobalData
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments
Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat
How To Trade (VRDN) - Stock Traders Daily
VRDN Factor-Based Stock Analysis - Nasdaq
Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
SG Americas Securities LLC Has $374,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week HighTime to Buy? - MarketBeat
Viridian Therapeutics Inc (VRDN) stock analysis: A comprehensive overview - US Post News
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Millennium Management LLC - MarketBeat
Financial Snapshot: Analyzing Viridian Therapeutics Inc (VRDN)’s Key Ratio Metrics - The Dwinnex
Dimensional Fund Advisors LP Purchases 97,510 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics Inc [VRDN] Records 50-Day SMA of $18.29 - Knox Daily
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Up 6.4%Should You Buy? - MarketBeat
Viridian Therapeutics Inc (VRDN) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
The growth track for Viridian Therapeutics Inc (VRDN) has changed recently - SETE News
Stock Performance Spotlight: Viridian Therapeutics Inc (VRDN) Ends the Day at 23.40, Up by 0.60 - The Dwinnex
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):